• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Kad­mon kicks off 're­al-time' NDA sub­mis­sion with an­oth­er look at 're­mark­able' chron­ic graft-ver­sus-host-dis­ease da­ta

5 years ago
R&D

Once val­ued at $4B, an em­bat­tled Ako­rn — nurs­ing a mar­ket cap of rough­ly $37M — files for bank­rupt­cy

5 years ago
Pharma
FDA+

Be­zos, Paul Allen funds, a16z put up $100M to build an Il­lu­mi­na of hu­man pro­teins

5 years ago
Financing
Startups

As CEO bounces back from Covid-19, Apel­lis says FDA meet­ing clears path to file for an OK on Soliris ri­val

5 years ago
R&D
FDA+

HotSpot an­nounces $65M Se­ries B, as Nim­bus pi­o­neers look to keep up in a crowd­ing field

5 years ago
R&D

Gilead, Gala­pa­gos claim PhI­Ib/III win for fil­go­tinib in ul­cer­a­tive col­i­tis — which pales in com­par­i­son to ri­vals

5 years ago
R&D

EMA ex­tends vir­tu­al-on­ly meet­ing pol­i­cy through Au­gust

5 years ago
FDA+
Coronavirus

Covid-19 roundup: BAR­DA hands As­traZeneca $1B-plus to race through PhI­II and ramp up fall de­liv­er­ies of Ox­ford’s ...

5 years ago
Coronavirus

Mam­moth Bio­sciences teams with GSK to put Covid-19 CRISPR tests at home, air­ports, bor­ders

5 years ago
Coronavirus

Covid-19 roundup: Hit with new con­flict ac­cu­sa­tions, Janet Wood­cock steps out of the agen­cy's Covid-19 chain of ...

5 years ago
R&D
Coronavirus

Si­lence Ther­a­peu­tics wants to list on Nas­daq while pur­su­ing new deals; Sur­face On­col­o­gy inks lat­est Keytru­da ...

5 years ago
News Briefing

Phar­mas­set co-founder jumps in­to Covid-19 fight, with a new com­pa­ny and $215 mil­lion to get there

5 years ago
Financing
Coronavirus

An­dreessen Horowitz backs a new mol­e­cule builder from UCLA equipped with the lat­est in con­ver­gence tech. And he’s ...

5 years ago
People
Financing

George Church spin­off swal­lows a key man­u­fac­tur­ing part­ner as it preps CRISPR-edit­ed pig or­gans for an­i­mal test­ing

5 years ago
Deals

A lit­tle-known biotech run­ning low on cash looks to get its own $100M IPO from pan­dem­ic mar­ket

5 years ago
Financing

Flush with $165M IPO cash, Zen­tal­is en­tices Ty­bourne, Or­biMed to fund a $20M Chi­na joint ven­ture

5 years ago
Financing

FDA, Ae­tion part­ner on re­al-world da­ta an­a­lyt­ics for Covid-19

5 years ago
FDA+
Coronavirus

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

5 years ago
Pharma
FDA+

Al­ly Bridge joins Bain in $120M bet that speed­ing up man­u­fac­tur­ing QC can hit big in post-pan­dem­ic world

5 years ago
Financing
Outsourcing

How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

5 years ago
R&D
Coronavirus

No­var­tis taps Iya Khalil, physi­cist co-founder of GNS Health­care, to lead AI In­no­va­tion Cen­ter

5 years ago
People
AI

Kin­tor Phar­ma­ceu­ti­cals com­pletes $240 mil­lion IPO; WuXi Bi­o­log­ics is open­ing a Boston plant

5 years ago
News Briefing

'Tis the sea­son for bio­phar­ma fundrais­ing, as Cowen clos­es $493M fund

5 years ago
Financing

BAR­DA of­fers a tiny start­up up to $812M to cre­ate a US-based drug man­u­fac­tur­er — and the CEO comes with a price ...

5 years ago
Startups
Deals
First page Previous page 825826827828829830831 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times